Genes (Basel):中频听力损失是OTOA相关听力损失的临床特性

2019-09-28 AlexYang MedSci原创

OTOA基因(DFNB22)是非综合中常染色体隐性听力损失的致病基因。该基因的拷贝数变异(CNVs)也能够引起听力损失,但是在日本患者听力损失中尚未得到鉴定。另外,OTOA相关的听力损失的临床特性也没有阐明。最近,有研究人员对一个大的日本听力损失患者群体进行了CNV分析,在2262名常染色体隐性听力损失患者中鉴定了234名患者存在CNVs(10.3%, 234/2262)。在鉴定的CNVs中,OT

OTOA基因(DFNB22)是非综合中常染色体隐性听力损失的致病基因。该基因的拷贝数变异(CNVs)也能够引起听力损失,但是在日本患者听力损失中尚未得到鉴定。另外,OTOA相关的听力损失的临床特性也没有阐明。

最近,有研究人员对一个大的日本听力损失患者群体进行了CNV分析,在2262名常染色体隐性听力损失患者中鉴定了234名患者存在CNVs(10.3%, 234/2262)。在鉴定的CNVs中,OTOA基因相关的CNVs频率排列第二(0.6%,14/2262)。在该14个案例中,2名个体携带OTOA纯合缺失,4名携带杂合缺失,另一个等位基因为单核苷酸变异(SNVs)。另外,研究人员还在OTOA基因中鉴定了1名纯和SNVs。最后,研究人员鉴定了7名OTOA相关听力损失的渊源者,因此,研究人员推算日本常染色体隐性听力损失患者的比例为0.3%(7/2262)。

最后,研究人员指出,作为新的临床特性,OTOA相关听力损失患者为中频听力损失。他们的研究也是首次阐释了OTOA基因变异或者缺失引起的听力损失的详细临床特征。

原始出处:

Sugiyama K, Moteki H, Kitajiri SI et al. Mid-Frequency Hearing Loss Is Characteristic Clinical Feature of OTOA-Associated Hearing Loss. Genes (Basel). 16 Sep 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044939, encodeId=fe5d204493977, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Jun 04 20:46:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040342, encodeId=e2982040342e6, content=<a href='/topic/show?id=978b13533ad' target=_blank style='color:#2F92EE;'>#OTOA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13533, encryptionId=978b13533ad, topicName=OTOA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Mar 09 02:46:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049232, encodeId=08c22049232e8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Feb 29 12:46:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306431, encodeId=8b5d1306431ab, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Sep 30 14:46:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373343, encodeId=8c223e33437d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Sun Sep 29 12:18:10 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044939, encodeId=fe5d204493977, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Jun 04 20:46:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040342, encodeId=e2982040342e6, content=<a href='/topic/show?id=978b13533ad' target=_blank style='color:#2F92EE;'>#OTOA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13533, encryptionId=978b13533ad, topicName=OTOA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Mar 09 02:46:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049232, encodeId=08c22049232e8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Feb 29 12:46:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306431, encodeId=8b5d1306431ab, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Sep 30 14:46:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373343, encodeId=8c223e33437d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Sun Sep 29 12:18:10 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2020-03-09 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044939, encodeId=fe5d204493977, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Jun 04 20:46:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040342, encodeId=e2982040342e6, content=<a href='/topic/show?id=978b13533ad' target=_blank style='color:#2F92EE;'>#OTOA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13533, encryptionId=978b13533ad, topicName=OTOA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Mar 09 02:46:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049232, encodeId=08c22049232e8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Feb 29 12:46:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306431, encodeId=8b5d1306431ab, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Sep 30 14:46:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373343, encodeId=8c223e33437d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Sun Sep 29 12:18:10 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2020-02-29 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044939, encodeId=fe5d204493977, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Jun 04 20:46:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040342, encodeId=e2982040342e6, content=<a href='/topic/show?id=978b13533ad' target=_blank style='color:#2F92EE;'>#OTOA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13533, encryptionId=978b13533ad, topicName=OTOA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Mar 09 02:46:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049232, encodeId=08c22049232e8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Feb 29 12:46:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306431, encodeId=8b5d1306431ab, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Sep 30 14:46:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373343, encodeId=8c223e33437d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Sun Sep 29 12:18:10 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2019-09-30 ysjykql
  5. [GetPortalCommentsPageByObjectIdResponse(id=2044939, encodeId=fe5d204493977, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Jun 04 20:46:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040342, encodeId=e2982040342e6, content=<a href='/topic/show?id=978b13533ad' target=_blank style='color:#2F92EE;'>#OTOA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13533, encryptionId=978b13533ad, topicName=OTOA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Mar 09 02:46:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049232, encodeId=08c22049232e8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Feb 29 12:46:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306431, encodeId=8b5d1306431ab, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Mon Sep 30 14:46:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373343, encodeId=8c223e33437d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Sun Sep 29 12:18:10 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2019-09-29 Dr Z

    学习了

    0

相关资讯

Int J Pediatr Otorhinolaryngol:1型糖尿病对儿童和青少年传出听觉系统的影响

最近,有研究人员通过分析内侧橄榄耳蜗反射的激活与病程、代谢控制和诊断时的年龄关系,调查了是否1型糖尿病(T1DM)能够影响传出听觉系统。研究总共包括了101名儿童和青少年,并分成了2个小组:具有T1DM组和不具有T1DM组。研究发现,与不具有T1DM疾病组相比,T1DM组所有参与者2只耳朵在所有的频率下AR均有变化(增加或者缺失),而DPOAE强度方面则没有发现差异。研究人员在内侧橄榄耳蜗反射(M

Int J Audiol:慢性鼻窦炎患者中存在隐性听力损失么?

最近,有研究人员调查了是否在慢性鼻窦炎(CRS)中听觉功能具有损伤。研究总共包括了85名患者,并分配到CRS组(n=65)或者单纯鼻中隔偏曲组(n=20)。两个小组均没有感觉神经性耳聋的其他风险因子,并表现出了正常的听觉阈值。研究还包括了没有CRS或者单纯鼻中隔偏曲的对照组(n=30),并且性别和年龄上与患者组匹配。研究人员进行了听觉测试分析,包括了纯音听觉、声阻抗测试、畸变产物耳声发射(DPOA

盘点:听力损失治疗进展

【1】Sci Rep:电触觉增强人工耳蜗使用者的噪声中语音表现研究 https://www.ncbi.nlm.nih.gov/pubmed/31388053耳蜗移植(CI)使用者通过他们的移植体仅能够获得有限的信息,意味着他们在噪音环境下理解语言仍旧存在困难。之前的研究表明了组合CI电信号和触觉信号能够提供关键的丢失的声音信息(电触觉刺激,EHS),从而改善噪音中的言语识别能力。最近,有研究人

JCI Insight:病毒诱导的耳蜗炎症能够改变听觉功能

尽管人类巨细胞病毒(HCMV)是一个已知的先天性HCMV感染(cCMV)新生儿感觉神经性听力损失的一个起因,而导致上述感觉神经性听力损失(SNHL)的机制仍旧还没有很好的阐释。最近,有研究人员利用一个听觉功能正在发育的CMV感染小鼠模型展示了小鼠CMV(MCMV)外周感染的新生小鼠能够产生耳蜗感染和病毒诱导的耳蜗炎症。大约50%-60%的感染小鼠表现出了在一定声音频率范围内听觉脑干响应(ABR)阈

Ear Hear:慢性传导性听力损失与言语理解力缺陷相关

最近,有研究人员确定了是否慢性声音剥夺能够导致人类更差的言语分别能力。研究人员对240名患者的听力情况进行了分析,这些患者具有正常的和对称的两侧骨传导听力阈值,且这些患者与不同病因的急性或者慢性单边传导性听力损失有关。研究人员发现,患有慢性传导性听力损伤和中度到一定程度的重度听力损失的患者的认知得分更低。受损的严重程度与言语认知表现显著相关,尤其是那些先天性畸形的患者中更为明显。当传导性损伤为急性

Int J Pediatr Otorhinolaryngol:耳蜗移植对儿童攻击性行为的影响

之前的研究已表明与具有正常听力的同龄人相比,更高程度的听力损失可能会引起更严重的外化(比如攻击性)和内化(比如抑郁和焦虑)行为问题。最近,有研究人员调查了通过耳蜗移植(CIs)增强声音对波斯儿童攻击性行为的影响情况。研究是一个前瞻性的研究,包括了72名儿童(40名女孩,32名男孩),他们经历了单边耳蜗移植。研究还包括了72名儿童(40名女孩,32名男孩)且年龄匹配的正常听力儿童为对照组。所有的CI